Basket Study to Assess Efficacy, Safety and PK of Iptacopan (LNP023) in Autoimmune Benign Hematological Disorders
Phase 2
Terminated
- Conditions
- Immune Thrombocytopenia (ITP)Cold Agglutinin Disease (CAD)
- Interventions
- First Posted Date
- 2021-10-21
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 19
- Registration Number
- NCT05086744
- Locations
- 🇬🇧
Novartis Investigative Site, London, United Kingdom
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Drug-drug Interaction Study of Ganaplacide and Lumefantrine With Itraconazole
Phase 1
Completed
- Conditions
- Malaria
- Interventions
- First Posted Date
- 2021-10-20
- Last Posted Date
- 2022-10-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 19
- Registration Number
- NCT05084651
- Locations
- 🇬🇧
Novartis Investigative Site, Belfast, Northern Ireland, United Kingdom
Study to Assess the Effect of Ofatumumab in Treatment Naïve, Very Early RRMS Patients Benchmarked Against Healthy Controls.
Phase 4
Active, not recruiting
- Conditions
- Relapse Remitting Multiple Sclerosis
- Interventions
- First Posted Date
- 2021-10-20
- Last Posted Date
- 2025-04-06
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 180
- Registration Number
- NCT05084638
- Locations
- 🇺🇸
Sibyl Wray MD Neurology PC, Knoxville, Tennessee, United States
🇺🇸MD First Research, Chandler, Arizona, United States
🇺🇸Barrow Neurological Clinics at St Josephs Hospital and MC, Phoenix, Arizona, United States
Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (IRIS Study)
- First Posted Date
- 2021-10-19
- Last Posted Date
- 2021-10-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 9456
- Registration Number
- NCT05082415
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Pharmacokinetic (PK) and Safety Study of Iptacopan (LNP023) in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Matched Control Healthy Participants With Normal Hepatic Function.
- First Posted Date
- 2021-10-14
- Last Posted Date
- 2023-07-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 38
- Registration Number
- NCT05078580
- Locations
- 🇺🇸
Novartis Investigative Site, San Antonio, Texas, United States
Safety and Efficacy of Intravenous OAV101 (AVXS-101) in Pediatric Patients With Spinal Muscular Atrophy (SMA) (OFELIA)
Phase 4
Completed
- Conditions
- Muscular Atrophy, Spinal
- Interventions
- Genetic: OAV101
- First Posted Date
- 2021-10-11
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 16
- Registration Number
- NCT05073133
- Locations
- 🇧🇷
Novartis Investigative Site, Sao Paulo, SP, Brazil
Survey Among Healthcare Professionals Treating Patients With Metastatic Breast Cancer in Selected European Countries to Evaluate Their Knowledge on Management of Hyperglycemia When Using Alpelisib
Completed
- Conditions
- Breast Cancer
- Interventions
- Other: Piqray Prescriber's/HCP guide for hyperglycemia
- First Posted Date
- 2021-10-11
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 103
- Registration Number
- NCT05073120
- Locations
- 🇨🇭
Novartis Investigative Site, Basel, Switzerland
A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer
Phase 1
Active, not recruiting
- Conditions
- Prostate Cancer Metastatic
- Interventions
- Drug: ARV-766 Part A&B
- First Posted Date
- 2021-10-05
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 152
- Registration Number
- NCT05067140
- Locations
- 🇺🇸
Clinical Trial Site, Madison, Wisconsin, United States
Characteristics of Patients With Neovascular Age-related Macular Degeneration Enrolled in the Brolucizumab Patient Support Services Program
Completed
- Conditions
- Age-related Macular Degeneration (AMD)
- Interventions
- Other: All participants
- First Posted Date
- 2021-10-04
- Last Posted Date
- 2021-10-12
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 18457
- Registration Number
- NCT05066685
- Locations
- 🇺🇸
Novartis Investigative Site, East Hanover, New Jersey, United States
A Safety and Efficacy Study of Remibrutinib in the Treatment of CSU in Japanese Adults Inadequately Controlled by H1-antihistamines
- First Posted Date
- 2021-09-17
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 71
- Registration Number
- NCT05048342
- Locations
- 🇯🇵
Novartis Investigative Site, Osaka, Japan
© Copyright 2025. All Rights Reserved by MedPath